肝硬化合并肠系膜上静脉栓塞患者2年预后预测模型的构建与验证

doi:10.3969/j.issn.1006-7795.2023.01.016

摘要/Abstract

摘要： 目的探讨肝硬化合并肠系膜上静脉栓塞(superior mesenteric venous thrombosis, SMVT)长期预后的影响因素,构建2年预后预测模型并进行预测效果评价。方法采集2016年12月至2020年3月确诊的肝硬化合并 SMVT患者254人的临床信息,以2019年3月30日为时间节点分为建模组(170例)和验证组(84例)。建模组依据随访2年时的结局分为生存组(148例)和死亡组(22例),运用多因素Logistic回归分析患者预后影响因素,建立模型并绘制列线图;采用受试者工作特征(receiver operating characteristic, ROC)曲线、校准曲线和Hosmer-Lemeshow 拟合优度检验评价预测模型的准确性、区分度和校准度;决策曲线分析(decision curve analysis,DCA)评估预测模型的临床有效性。结果年龄(HR=4.625,95% CI:1.493~14.322,P=0.008)、粒细胞/淋巴细胞比值(neutrophils/lymphocyte ratio, NLR)(HR=4.650,95% CI:1.343~16.099,P=0.015)为肝硬化合并SMVT患者预后的独立影响因素;预测模型公式为PI=－4.753+1.531×年龄+1.537×NLR;曲线下面积(area under the curve,AUC)为 0.838(95%CI:0.751~0.925),当预测截点(cut-off)值为0.070时,灵敏度=86.4%,特异度=62.8%;内部验证的AUC为0.806,灵敏度为81.8%,特异度为79.4%,Kappa=0.408。Hosmer-Lemeshow 拟合优度检验显示出较好的拟合度(建模队列P=0.494;验证队列P=0.128)。DCA 结果显示阈值概率>10%,预测模型在临床上是有益的。结论年龄、NLR是肝硬化合并SMVT患者2年预后的独立影响因素;本研究建立的模型在预测此类患者的2年预后方面具有一定应用价值。

关键词: 肝硬化, 肠系膜上静脉栓塞, 危险因素, 预测模型

Abstract: Objective To investigate the influencing factors of long-term prognosis of liver cirrhosis complicated with superior mesenteric venous thrombosis (SMVT). Methods The clinical information of 254 patients with liver cirrhosis complicated with SMVT diagnosed from December 2016 to March 2020 was collected. Taking March 30, 2019 as the time point, the patients were divided into modeling group (170 cases) and validation group (84 cases). The modeling group was divided into survival group (148 cases) and death group (22 cases) according to the outcome of follow-up for 2 years. The influencing factors of prognosis were analyzed by Logistic regression and the model was established. The receiver operating characteristic (ROC)curve,calibration curves, and Hosmer-Lemeshow test were used to validate and evaluate the discrimination and calibration of the model, while the decision curve analysis was used to evaluate its clinical validity. Results Age(HR=4.625,95% CI:1.493－14.322,P=0.008), neutrophils/lymphocyte ratio (NLR) (HR=4.650,95% CI:1.343－16.099,P=0.015) were independent prognostic factors in patients with liver cirrhosis complicated with SMVT. Calculation formula of prediction model is PI=－4.753+1.531×age+1.537×NLR. The area under the curve(AUC) of the predictive scoring model was 0.838(95%CI:0.751－0.925), the sensitivity was 86.4%, the specificity was 62.8%; The AUC of internal validation was 0.806, the sensitivity was 81.8%, and the specificity was 79.4%, Kappa=0.408.The Hosmer-Lemeshow test showed perfect fitting degree (modeling:P=0.494;validation:P=0.128). Decision curve analysis showed a risk threshold of 10% and demonstrated a clinically effective predictive model. Conclusion Age and NLR are independent factors affecting the 2-year prognosis of patients with liver cirrhosis complicated with SMVT. The model established in this study has certain application value in predicting the 2-year prognosis of such patients.

Key words: liver cirrhosis, superior mesenteric vein embolization, risk factors, prediction model

中图分类号:

R765. 4

冯颖, 时克, 王宪波. 肝硬化合并肠系膜上静脉栓塞患者2年预后预测模型的构建与验证[J]. 首都医科大学学报, 2023, 44(1): 107-114.

Feng Ying, Shi Ke, Wang Xianbo. Establishment and validation of 2-year predictive scoring model for patients with liver cirrhosis complicated with superior mesenteric venous thrombosis[J]. Journal of Capital Medical University, 2023, 44(1): 107-114.

参考文献

[1] Hmoud B, Singal A K, Kamath P S. Mesenteric venous thrombosis [J]. J Clin Exp Hepatol,2014,4(3):257－263.
[2] 王阳, 陈建立,陈俊卯,等. 肠系膜上静脉血栓形成临床特点及预后相关因素分析 [J]. 医学研究杂志,2017,46(8):103－105.
[3] Björck M, Koelemay M, Acosta S, et al. Editor's choice-management of the diseases of mesenteric arteries and veins: clinical practice guidelines of the European Society of Vascular Surgery (ESVS) [J]. Eur J Vasc Endovasc Surg, 2017,53(4):460－510.
[4] Salim S, Zarrouk M, Elf J, et al. Improved prognosis and low failure rate with anticoagulation as first-line therapy in mesenteric venous thrombosis [J]. World J Surg, 2018,42(11):3803－3811.
[5] 中华医学会肝病学分会. 肝硬化诊治指南 [J]. 临床肝胆病杂志,2019,35(11):2408－2425.
[6] 程瑞, 陈佩佩,林姹姹,等. 肠系膜血管超声与CTA对急诊急性肠系膜血管栓塞的诊断对比 [J]. 中国医药导报,2021,18(17):122－125.
[7] 王乔宇, 武明芬,柳鑫,等. 2021中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南 [J]. 中国临床药理学杂志,2021,37(21):2999－3016.
[8] 段志泉, 孙成林. 肠系膜静脉血栓形成的诊断与治疗 [J]. 中华医学杂志,2004,84(18):1572－1574.
[9] 李敏, 苏健婷, 武珊珊, 等. 乙型肝炎肝硬化患者年龄和性别与肝病相关死亡风险的关系 [J]. 中华肝脏病杂志, 2021, 29(5): 403－408.
[10] 宋子璇, 刘卫平. 老年血流感染患者的血液病原菌培养鉴定及耐药性观察、死亡风险预测模型构建 [J]. 山东医药,2022,62(3):10－15.
[11] 王瑞瑞, 江宇泳,王宪波,等. 酒精性肝硬化合并自发性细菌性腹膜炎患者长期预后预测模型的建立与验证 [J]. 肝脏,2020,25(10):1030－1033.
[12] Gao F, Zhang Q, Liu Y, et al. Nomogram prediction of individual prognosis of patients with acute-on-chronic hepatitis B liver failure [J]. Dig Liver Dis, 2019,51(3):425-433.
[13] 姜蕾, 金大伟,富宏然. 年龄对部分凝血指标的影响及临床意义 [J]. 中国实用医药,2007,2(14):71.
[14] 王宪波, 高方媛,刘尧.中性粒细胞与淋巴细胞比值:一项评价肝细胞癌患者预后的新指标 [J].临床肝胆病杂志,2016,32(04):649-652.
[15] Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage [J]. J Transl Med, 2020,18(1):206.
[16] Malarkannan S. Molecular mechanisms of FasL-mediated‘reverse-signaling' [J]. Mol Immunol, 2020,127:31-37.
[17] 王宪波, 曾辉. 粒细胞/淋巴细胞比值与乙型肝炎相关慢加急性肝衰竭:从预测结局到中医治疗策略的思考 [J]. 中西医结合肝病杂志,2016,26(3):129－132.
[18] Wang S, Liu H, Wang Q, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are effective predictors of prognosis in patients with acute mesenteric arterial embolism and thrombosis [J]. Ann Vasc Surg, 2018,49:115－122.
[19] Karadeniz E, Bayramoğlu A, Atamanalp S S. Sensitivity and specificity of the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio in diagnosing acute mesenteric ischemia in patients operated on for the diagnosis of mesenteric ischemia: a retrospective case-control study [J]. J Invest Surg, 2020,33(8):774-781.